{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:57:06Z","timestamp":1790351826384,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":303,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.lrr.2022.100358","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T21:46:55Z","timestamp":1667252815000},"page":"100358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Therapy-related B-lymphoblastic leukemia after multiple myeloma"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0470-7922","authenticated-orcid":false,"given":"Michael E.","family":"Kallen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Koka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeba N.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7299-1411","authenticated-orcid":false,"given":"Yi","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9888-5737","authenticated-orcid":false,"given":"Mehmet H.","family":"Kocoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf Z.","family":"Badros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Niyongere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu H.","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Emadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2022.100358_bib0001","unstructured":"Swerdlow S.H.C.E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Arber D.A., Hasserjian R.P., Le Beau M.M., Orazi A., Siebert R. WHO classification of tumours of hematopoietic and lymphoid tissues. Revised 4th edition ed. Lyon: IARC; 2017."},{"issue":"8","key":"10.1016\/j.lrr.2022.100358_bib0002","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.lrr.2022.100358_bib0003","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.lrr.2022.100358_bib0004","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.lrr.2022.100358_bib0005","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.lrr.2022.100358_bib0006","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lrr.2022.100358_bib0007","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lrr.2022.100358_bib0008","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjh.16764","article-title":"The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?","volume":"191","author":"Kazandjian","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lrr.2022.100358_bib0009","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.lrr.2022.100358_bib0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-022-00680-y","article-title":"Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma","volume":"12","author":"Parrondo","year":"2022","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.lrr.2022.100358_bib0011","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00277-008-0680-8","article-title":"Early onset of acute lymphoblastic leukemia with MLL rearrangement after autologous stem cell transplantation for multiple myeloma","volume":"88","author":"Ueda","year":"2009","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.lrr.2022.100358_bib0012","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.leu.2403587","article-title":"Acute lymphoblastic leukemia after tandem autologous stem cell transplantations for multiple myeloma","volume":"19","author":"Lau","year":"2005","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.lrr.2022.100358_bib0013","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3109\/10428194.2014.970543","article-title":"Therapy-related myelodysplastic syndrome\/acute leukemia after multiple myeloma in the era of novel agents","volume":"56","author":"Gertz","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lrr.2022.100358_bib0014","article-title":"Acute lymphoblastic leukemia following lenalidomide maintenance for multiple myeloma: two cases with unexpected presentation and good prognostic features","volume":"2018","author":"Khan","year":"2018","journal-title":"Case Rep. Hematol."},{"issue":"6","key":"10.1016\/j.lrr.2022.100358_bib0015","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/ajcp\/aqaa109","article-title":"Lenalidomide-associated secondary B-lymphoblastic leukemia\/lymphoma-A unique entity","volume":"154","author":"Germans","year":"2020","journal-title":"Am. J. Clin. Pathol."},{"issue":"12","key":"10.1016\/j.lrr.2022.100358_bib0016","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3109\/10428194.2013.786072","article-title":"Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma","volume":"54","author":"Garc\u00eda-Mu\u00f1oz","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.lrr.2022.100358_bib0017","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3892\/ol.2016.4728","article-title":"Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: a case report","volume":"12","author":"Li","year":"2016","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.lrr.2022.100358_bib0018","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hon.2248","article-title":"Lenalidomide and secondary acute lymphoblastic leukemia: a case series","volume":"35","author":"Tan","year":"2017","journal-title":"Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.lrr.2022.100358_bib0019","first-page":"219","article-title":"[B-cell acute lymphoblastic leukemia developed 5 years after autologous stem cell transplantation for multiple myeloma]","volume":"53","author":"Tsukada","year":"2012","journal-title":"Rinsho Ketsueki"},{"issue":"Suppl. 2","key":"10.1016\/j.lrr.2022.100358_bib0020","article-title":"Three patients with multiple myeloma developing secondary lymphoblastic leukemia: case reports and review of the literature","volume":"102","author":"Junxun","year":"2016","journal-title":"Tumori"},{"issue":"2","key":"10.1016\/j.lrr.2022.100358_bib0021","first-page":"176","article-title":"Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma","volume":"43","author":"Gonzalez","year":"2013","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"23","key":"10.1016\/j.lrr.2022.100358_bib0022","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.2020009141","article-title":"B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma","volume":"136","author":"Tashakori","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lrr.2022.100358_bib0023","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ccr3.1264","article-title":"Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure","volume":"6","author":"Alhuraiji","year":"2018","journal-title":"Clin. Case Rep."},{"issue":"4","key":"10.1016\/j.lrr.2022.100358_bib0024","first-page":"287","article-title":"Acute B lymphoblastic leukemia developing in patients with multiple myeloma: presentation of two cases","volume":"36","author":"Mei","year":"2019","journal-title":"Turk. J. Haematol."},{"issue":"1","key":"10.1016\/j.lrr.2022.100358_bib0025","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1186\/s12885-019-6286-9","article-title":"B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review","volume":"19","author":"Sinit","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.lrr.2022.100358_bib0026","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3343\/alm.2019.39.5.496","article-title":"Two rare cases of therapy-related acute lymphoblastic leukemia in patients with plasma cell myeloma","volume":"39","author":"Lee","year":"2019","journal-title":"Ann. Lab. Med."},{"issue":"1","key":"10.1016\/j.lrr.2022.100358_bib0027","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41375-018-0213-y","article-title":"Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma","volume":"33","author":"Aldoss","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.lrr.2022.100358_bib0028","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00277-016-2762-3","article-title":"Allogeneic bone marrow transplantation for therapy-related acute lymphocytic leukemia after autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"95","author":"Konishi","year":"2016","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.lrr.2022.100358_bib0029","first-page":"593","article-title":"Secondary acute lymphoblastic leukaemia in a multiple myeloma patient","volume":"16","author":"Piszcz","year":"2012","journal-title":"Contemp. Oncol. (Pozn)"},{"issue":"4","key":"10.1016\/j.lrr.2022.100358_bib0030","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/bjh.17906","article-title":"Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia","volume":"196","author":"Abdel Rahman","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.lrr.2022.100358_bib0031","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1002\/ajh.24604","article-title":"Philadelphia chromosome as a recurrent event among therapy-related acute leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.lrr.2022.100358_bib0032","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lrr.2022.100358_bib0033","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cancergencyto.2007.09.005","article-title":"A novel t(3;19)(p21;p13) in a patient with acute myelocytic leukemia","volume":"179","author":"Zhu","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"issue":"8","key":"10.1016\/j.lrr.2022.100358_bib0034","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41375-021-01293-3","article-title":"The mutagenic impact of melphalan in multiple myeloma","volume":"35","author":"Maura","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.lrr.2022.100358_bib0035","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3324\/haematol.2018.193599","article-title":"Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.lrr.2022.100358_bib0036","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1182\/bloodadvances.2019000925","article-title":"Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes","volume":"3","author":"Saygin","year":"2019","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.lrr.2022.100358_bib0037","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1038\/s41375-020-01061-9","article-title":"Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome","volume":"35","author":"Barnea Slonim","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.lrr.2022.100358_bib0038","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1080\/16078454.2022.2074704","article-title":"Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia","volume":"27","author":"Shi","year":"2022","journal-title":"Hematology"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:08:21Z","timestamp":1761959301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048922000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":38,"alternative-id":["S2213048922000693"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100358","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy-related B-lymphoblastic leukemia after multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100358"}}